|
Impliant has received clearance from the FDA to study the TOPSTM System in the US according to a randomized controlled study protocol. The trial will take place at leading spine centers across the country.
|
Read More
|
|
|
|
|
 |
Company
News
Impliant Restarts European Clinical Activities for Patented TOPS™ Spine System
Jul. 3, 2008
|
|
Princeton, NJ – June 26, 2008 – Impliant, Inc., a developer of novel spine arthroplasty alternatives to fusion surgery, today announced that it has resumed European clinical activities on its TOPS™ System, a Total Posterior Arthroplasty device designed to treat spinal stenosis with or without facet arthrosis and spondylolisthesis. The procedure was performed by the Lead Clinician of the London Spine Clinic, Mr. John C. Sutcliffe, MB ChB, FRCS.
|
|
|
|
Impliant Restarts Pivotal Clinical Trial for Patented TOPS™ System
May. 25, 2008
|
|
Princeton, NJ – Impliant, Inc., a developer of novel spine arthroplasty alternatives to fusion surgery, today announced that it has received FDA approval to restart patient enrollment in a pivotal IDE trial of its TOPS™ System, a Total Posterior Arthroplasty device designed to treat spinal stenosis with or without facet arthrosis and spondylolisthesis.
|
|
|
|
Impliant Enrolls First Patient in Clinical Trial for the TOPS-on-Fusion™ System, the First Integrated Motion Preservation System for Spinal Fusion Patients
Oct. 24, 2006
|
|
Milford, CT – Impliant, Inc., a developer of novel spine arthroplasty alternatives to fusion surgery, announced that it has enrolled its first patient in a trial of its two-level TOPS-on-Fusion™ System.
|
|
|
|
Impliant Enrolls First Patient in Pivotal US Clinical Trial for the TOPS™ System, an Alternative to Spinal Fusion
Sep. 25, 2006
|
|
Milford, CT – Impliant, Inc., a developer of novel spine arthroplasty alternatives to fusion surgery, today announced that it has enrolled its first patient in a pivotal IDE trial of its TOPS™ System, a Total Posterior Arthroplasty device designed to treat spinal stenosis with or without facet arthrosis and spondylolisthesis.
|
|
|
|
Impliant Receives FDA Approval to Begin Pivotal Clinical Trial for Patented TOPS™ System
Aug. 23, 2006
|
|
Milford, CT – Impliant, Inc., a developer of novel spine arthroplasty alternatives to fusion surgery, today announced that it has received Conditional Approval from the FDA to enroll patients in a pivotal IDE trial.
|
|
|
|
TOPS™ System Gains CE Approval
Jun. 15, 2006
|
|
Ramat Poleg, Israel – Impliant announced today that the Company has received CE approval for its patented TOPS™ System, the world’s first total posterior motion preservation system to address facet arthosis, spondylolisthesis, and spinal stenosis.
|
|
|
|
Impliant Presents One-Year Follow-up on World’s Longest Posterior Spine Arthroplasty Series
May. 15, 2006
|
|
Milford, CT – Impliant, Inc., a developer of novel spine arthroplasty alternatives to fusion surgery, today announced that Larry Khoo, M.D., one of the investigators involved in the Company’s clinical trial with its TOPS™ System, presented outcome data on twenty patients, including one-year follow-up data on five spine arthroplasty patients, who received the patented TOPS™ System for treatment of facet arthosis, spondylolisthesis, and spinal stenosis at the Spine Arthroplasty Society Meeting in Montreal, Canada yesterday.
|
|
|
|
Impliant Awarded Two Key US Patents for Spine Motion Preservation
May. 5, 2006
|
|
Milford, CT – Impliant, Inc., a developer of novel spine arthroplasty alternatives to fusion surgery, today announced that its wholly-owned subsidiary, Impliant, Ltd., has been awarded two United States patents for its spinal implant solutions in posterior motion preservation.
|
|
|
|
|
